Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine
BMC Psychiatry January 4, 2026 Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson et al. 2 citations
Abstract Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation...